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SINTESIS, STRUKTUR DAN CIRI ANTIMIKROB KOMPLEKS 
ARGENTUM(I)- DAN PALLADIUM(II)-N-HETEROSIKLIK KARBENA 
BARU TERBITAN [BENZ]IMIDAZOL-2-ILIDENA  
ABSTRAK 
Tesis ini melaporkan sintesis, struktur dan ciri antimikrob pelbagai kompleks 
argentum (I)- dan palladium(II)-NHC mengandungi ligan [benz]imidazolin-2-ilidena. 
Hasil penemuan penyelidikan ini dibentangkan dalam empat bab. Dua jenis garam 
[benz]imidazolium dengan gantian yang berlainan telah disediakan. Jenis yang 
pertama ialah garam mono-[benz]imidazolium (1-15) yang berteraskan eter, nitril 
dan alil. Kesemua garam mudah diubah dengan menggunakan gantian akil/akil aril 
pada posisi ketiga pada gelang [benz]imidazolium. Manakala jenis yang kedua ialah 
garam bis-[benz]imidazolium (16-25) terbitan sistem terangkai propil, piridina dan 
para-xilena. Kompleks disediakan melalui tindakbalas in situ Ag2O dengan garam 
[benz]imidazolium sepadan secara mempelbagaikan nisbah molar logam kepada 
garam, menghasilkan dua puluh lima kompleks Ag(I)-NHC (26-50) yang baru. 
Struktur krystal sinaran-X bagi lima belas kompleks telah ditentukan dan 
menunjukkan variasi dalam corak stuktur merentangi siri dengan spesies 
mononuklear dan dinuklear. Garam dan kompleks telah dicirikan dengan kaedah 
spektroskopi (FTIR, 
1
H dan 
13
C NMR), analisis unsur (CHN) dan kaedah 
pembelauan sinaran-X kristal tunggal. Kesan daripada gantian yang berbeza pada 
kompleks ke atas aktiviti antibakteria telah diuji. Efikasi antibakteria bagi sebatian 
telah diperiksa dengan menggunakan Staphylococcus aureus (ATCC 12600) sebagai 
bakteria Gram positif dan Escherichia coli (ATCC 25922) sebagai bakteria Gram 
negatif. Kesemua kompleks Ag(I)-NHC, secara umumnya, menunjukkan aktiviti 
antibakteria yang baik dengan nilai dalam lingkungan 10.0±0.5-32.9±2 mm untuk 
zon perencatan tumbuhan bakteria dan nilai MIC untuk kompleks adalah dalam 
xxx 
 
lingkungan 6.25-100 μg/ mL. Walau bagaimanapun, garam berkaitan adalah tidak 
aktif pada dasarnya bagi kedua-dua stren bakteria. Adalah diperhatikan bahawa 
terbitan kompleks Ag(I)-NHC dengan rantaian akil yang lebih panjang bersifat lebih 
bioaktif. Seterusnya keputusan juga menyokong bahawa kompleks Ag(I)-NHC 
dinuklear mempunyai potensi antibakteria yang lebih baik daripada seiring 
mononuklear mereka. Untuk memperolehi pandangan tempoh awal pada mod 
tindakan sebenar mereka, plasmid pekeliling pTS414 DNA/RNA telah didedahkan 
pada gel elektroforesis dan didapati Ag(I)-NHC mononuklear (31, 34, 37, dan 38) 
dan Ag(I)-NHC dinuklear (41, 44, 45, 46 dan 48) adalah sangat efisien dalam 
menggalakkan rekahan/degradasi RNA dan DNA tanpa kehadiran zat tindakbalas 
iaitu dalam ketidakhadiran H2O2 dan reduktan tambahan.  
Sintesis CNC bersepadu kompleks Pd(II)-NHC telah dicapaikan melalui 
tindakbalas pentranslogaman (pemindahan NHC) antara Pd(cod)Cl2 dengan 
kompleks Ag(I)-NHC terbitan garam bis-[benz]imidazolium yang berkenaan. Kajian 
sinaran-X menunjukkan struktur mononuklear untuk tiga kompleks (52, 54 dan 55) 
dalam keadaan pepejal. Kompleks Pd(II)-NHC yang disediakan telah diuji dengan E. 
coli dan S. aureus. Kompleks yang diuji menunjukkan aktiviti pada bakteria yang 
disebut, tetapi lebih rendah dibandingkan dengan kompleks Ag(I)-NHC. Keputusan 
daripada aktiviti nuklease tempoh awal menunjukkan kompleks Pd(II)-NHC (51, 52, 
54 and 55) adalah efisien dalam rekahan asid nukleik melalui mekanisme tak 
teroksidasi. 
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SYNTHESIS, STRUCTURE AND ANTIMICROBIAL PROPERTIES OF 
NEW SILVER(I)- AND PALLADIUM(II)-N-HETEROCYCLIC CARBENE 
COMPLEXES DERIVED FROM [BENZ]IMIDAZOL-2-YLIDENES 
 
ABSTRACT 
This thesis reports the synthesis, structure and antimicrobial properties of various 
silver(I)- and palladium(II)-NHC complexes bearing [benz]imidazolin-2-ylidene 
ligands. The findings of the research are presented in four chapters. Two types of 
[benz]imidazolium salts with different substituents were prepared. The first type is 
mono-[benz]imidazolium salts (1-15) with ether, nitrile and allyl functionalities. 
They are conveniently tuned, using different alkyl/alkyl aryl substituents at the 3-
position of the [benz]imidazolium ring. While the second type is bis-
[benz]imidazolium salts (16-25) derived from propyl, pyridine and para-xylene 
linked systems. The complexes were prepared by in situ reaction of Ag2O with the 
corresponding [benz]imidazolium salts by varying the metal to salt molar ratio, 
resulting in the isolation of twenty five new Ag(I)-NHC complexes (26-50). X-ray 
crystal structures for fifteen of these complexes were determined showing a variation 
in the structural motifs across the series with mononuclear and binuclear species 
being generated. The salts and their complexes were characterized by spectroscopic 
methods (FTIR, 
1
H and 
13
C NMR), elemental analysis (CHN) and single crystal X-
ray diffraction techniques. The effect of substitutions on antibacterial activity of 
these compounds has been investigated. Compounds were screened for their 
antibacterial efficacy against Staphylococcus aureus (ATCC 12600) as a Gram 
positive bacterium and Escherichia coli (ATCC 25922) as a Gram negative 
bacterium. All the Ag(I)-NHC complexes, in general, showed good antibacterial 
activities in the range 10.0±0.5-32.9±2 mm for the zone of bacterial growth 
inhibition and the MIC values of the complexes are in the range of 6.25-100 μg/ mL. 
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However, their corresponding salts were essentially inactive against both strains of 
bacteria. It was observed that the derivatives of the Ag(I)-NHC complexes with 
longer alkyl chain were more bioactive. Furthermore the results also suggest that 
binuclear Ag(I)-NHC complexes have relatively better antibacterial potential 
compared with their mononuclear counterparts. In order to gain preliminary insights 
into their actual mode of action(s), circular plasmid pTS414 DNA/RNA was exposed 
to gel electrophoresis and it was found that the mononuclear Ag(I)-NHC (31, 34, 37 
and 38) and binuclear Ag(I)-NHC (41, 44, 45, 46 and 48) are extremely efficient in 
promoting the cleavage/degradation of RNA and DNA in the absence of  co-
reactants  i.e., in the absence of H2O2 and added reductant. 
The synthesis of CNC pincer Pd(II)-NHC complexes has been achieved by 
the transmetallation (NHC transfer) reaction between Pd(cod)Cl2 and the 
corresponding Ag(I)-NHC complexes derived from bis-[benz]imidazolium salts. X-
ray studies revealed mononuclear structures for three of the complexes (52, 54 and 
55) in solid state. The prepared Pd(II)-NHC complexes were tested against the E. coli 
and S. aureus. The examined complexes showed an activity against the mentioned 
bacteria, but much lower than that of the Ag(I)-NHC complexes. The results of the 
preliminary nuclease activities demonstrate that Pd(II)-NHC (51, 52, 54 and 55) 
complexes are efficient in the cleavage of nucleic acids via non-oxidative 
mechanism. 
 
 
 
1 
 
CHAPTER ONE 
 
INTRODUCTION 
  
1.1       N-Heterocyclic Carbenes (NHCs)  
        NHCs are electron rich σ-donor ligands with zero formal charge on the 
carbene carbon.
1
 Generally, NHCs possess the carbene carbon located at the 2-
position between the two nitrogen substituents (Figure 1.1 a). They are singlet 
carbenes which are electronically and sterically stabilized. It is the inductive (-I) and 
the mesomeric (+M) push-pull effect that provides most of the stabilizing energy.
2,3,4
 
However, by changing the type of azole ring electronic properties can be adapted 
with the following order of electron donating power benzimidazole < imidazole < 
imidazoline (Figure 1.1 b).
5
  
NHCs have been found as efficient substitutes to phosphine ligands due to 
many advantages as ancillary ligands.
6 
The availability of sterically impeded 
functional group attached to the nitrogen atoms promotes reductive elimination of the 
product from the metal. The influence of the metal-carbene bond of the NHC 
complex facilitates ligand dissociation and they are also better σ-donors than 
phosphine ligands. Lastly the carbene carbon containing the unfilled orbitals is 
normally part of the heterocycle (azole ring system), therefore the properties of the 
NHCs can be finely tuned by the addition of electron donating substituents on the 
nitrogen atoms, affording them exceptional coordinating power and superior 
multidentate ligands.
7,8
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Figure 1.1: (a) Position of the carbene carbon (b) Order of electron donating                                        
                   power. 
            
1.2 Background 
Carbenes have been known as an exclusive type of intermediate, as far back 
as 1954 according to the earlier work by Doering.
9
 After the introduction of carbenes 
by Doering to organic chemistry
9
 and ten years later by Fischer and Maasbol to 
organometallic chemistry,
10
 they have attracted the interest of synthetic
11
 and 
organometallic
12
 chemists exceedingly. However it was not until Arduengo isolated 
and characterised the first stable NHC in 1991 (Scheme 1.1)
13
 that the interest of the 
scientific community was revived.
14-16 This discovery led to the use of NHC in the 
development of carbene system. After this, different methods for the isolation of 
heterocyclic carbenes have been reported by a number of research groups.
17,18,19,20
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Scheme 1.1:  Preparation of the first isolated NHC. 
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 NHCs have been known due to earlier work done in 1968 by Wanzlick and 
Ofele who were able to use them to form mercury-salt and chromate carbene 
complexes.
21,22
 The mercury complex was formed from the metal acetate, while 
Ofele used carbonyl metalate for the chromate complex (Scheme 1.2). The carbenes 
intermediate were claimed to have been prepared by in situ technique from 
corresponding imidazolium salts.
22
 
 
N
N
Ph
Ph
H2
N
N
Ph
Ph
Hg
N
N
Ph
Ph
Hg(OAc)2 
2AcOH
N
N
Me
Me
H
H2
N
N
Me
Me
Cr(CO)5
2
(a)
(b)
+
+ .2ClO4ClO4
[HCr(CO)5]
 
Scheme 1.2: Formation of NHC-metal complexes by (a) Wanzlick     
                     and (b) Öfele.
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 1.3 Structural diversities and stability 
NHCs possess several variations in their basic structures (Figure 1.2). 
Examples of these are imidazol-2-ylidene I, imidazolidin-2-ylidene II, a five-
membered 1, 2, 4-triazolin-(3, 5)-ylidene IV with the presence of carbenes at the 3 
and 5-positions, thereby enhancing the possibility of binding to one or more metal 
centres.
23 
Furthermore there is six membered tetrahydropyrimid-2-ylidine V
24
 and  
several other heterocyclic carbenes have already been reported, such as four-
4 
 
membered rings,
25
 1, 3-thiazole
26
, cyclic alkyl(amino)carbenes,
27,28
 P-heterocyclic 
carbenes (PHCs).
29,30
 
 
However five membered NHCs are the most broadly studied
31
. 
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Figure 1.2: Types of NHC ligands. 
The contributions of the 6 π-electrons in unsaturated NHCs to the stability of 
the carbene centre have been a disputable contention.
28,32
 NHCs of this type are 
proposed to stabilize the singlet state when there are unshared electrons paired in the 
same σ or π orbitals as a result of the inductive (-I) and the mesomeric (+M) push-
pull effect (Figure 1.3).
32
 Thus the negative inductive effect of the nitrogen on  the 
carbene carbon decreases the energy of σ non-bonding orbital by increasing it s-
character and leaving the Pπ orbital unaltered, thereby favouring the singlet state.16 
The mesomeric effect occurs when the carbon orbitals (s, pπ or px, py) interact with 
the p or π orbitals of the nitrogen substituents. The substituents lone pair improves 
the Pπ character of the singlet carbenes via electron transfer to the vacant Pπ orbitals 
of the carbenes.
16
  
Dixon and Arduengo formerly stated that the stability of NHCs was mainly as 
a result of the inductive charge transfer from the carbene carbon to the nitrogen 
substituents, and that the mesomeric effect is quite insignificant.
28,33
 It was also 
proposed that the double bond unsaturation would facilitate a delocalisation of 
5 
 
electron density around the ring, thereby providing a small but valid contribution to 
the overall stability of the NHC.
16,35-37
 
 
e- withdrawal
(inductive effect)
unshared electrons
vacant p-orbital
e- donation
(resonance effect)
 
Figure 1.3: Electronic stabilisation of NHCs. 
This was considered to have justified Arduengo’s isolation of a free carbene with an 
unsaturated backbone, while Wanzlick’s earlier work on saturated systems produced 
dimers.
38
 However in 1995, NHC bearing saturated backbone was isolated and it 
became clear that the contribution of delocalisation could only give little 
stabilisation.
18
 and that mesomeric π-electron donation from the nitrogen atoms to 
the carbene centre is adequate for the stabilisation of the free carbene.
35
 
 
1.4 Synthesis of azolium salts: the NHC precursors  
NHC precursors are prepared by two common pathways:
39
  
1.4.1  Nucleophilic substitution 
This route involves step-by-step alkylation of azole (imidazole, 
benzimidazole, triazole etc) in the presence of strong base such as KOH and NaOH. 
The potassium or sodium azolide formed is then treated with one equivalent of alkyl 
or aryl halide in a suitable solvent to obtain N-alkyl/aryl substituted azole.
40
 The N-
substituted azole is subsequently reacted with one equivalent of appropriate 
alkyl/aryl halide to yield disubstituted derivatives of imidazolium salts (Scheme 1.3).  
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 halide
+
X = Halide  
Scheme 1.3: Synthesis of [benz]imidazolium salts by nucleophilic substitution.
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1.4.2 Multi components one step reaction  
This route involves one pot synthesis, starting from glyoxal, primary amine 
and formaldehyde leading to the desired products. The reaction proceeds through a 
coupling between amine and glyoxal and forms the corresponding Schiff base. 
Condensation with formaldehyde leads to the imidazolium salt. The multicomponent 
reaction of primary amines, glyoxal, and formaldehyde in the presence of a Brønsted 
acid has been developed for the introduction of reactive N, N′-substituents (Scheme 
1.4).
41
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Scheme 1.4: Synthesis of imidazolium salt by multi-components reaction.
41
  
 
This flexible reaction gives access to a multitude of symmetrically N, N’-
substituted imidazolium salts. Unsymmetrical substituted azolium salts can also be 
prepared by the combination of a multicomponent cyclization with an N-alkylation 
reaction. The initial cyclization gives an N-alkyl imidazolium salt, which is then 
alkylated at the second nitrogen atom to obtain the asymmetrically substituted 
derivative (Scheme 1.5).
42
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Scheme 1.5: Multi-component cyclization and N-alkylation.
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1.5 Preparation of NHC complexes 
NHCs have been extensively used due to their favourable properties over 
phosphine and its strong coordination with main group and transition metals. 
Recently, researchers have adopted a number of synthetic procedures to prepare 
NHC complexes of d-block and main group metals.
43,44
 The outline of the main 
synthetic methods is presented in Scheme 1.6. 
(a)   Free Carbene Route 
       This method was achieved by the reaction of suitable metal compounds  with 
free NHCs. The deprotonation of the azolium salt results in the free NHC generation 
and the subsequent reaction with an appropriate metal compound to yield the 
transition metal carbene complex (Scheme 1.7).
45,46,47 
Free carbene route has been 
adopted in the preparation of vast array of metal complexes but the choice of this 
procedure is constrained due to the conditions needed to afford the free carbene. 
Strong bases such as KH or KO
t
Bu are often used and usually they can result in the 
deprotonation of some other acidic protons in the ligand. Therefore this method is 
limited to imidazolidin-2-ylidenes and benzimidazolin-2-ylidenes because the 
deprotonation can give rise to decomposition, especially in ligands where the 
methylene groups are in the α position of the nitrogen atoms of the NHC.48-50  
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Scheme 1.6: Primary synthetic routes towards formation of NHC complexes.
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Scheme 1.7: Synthesis of  Ag(I)-NHC via free carbene route.
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(b)   In situ deprotonation of azolium salts 
       This method is based on the deprotonation of azolium salts by the use of external 
bases such as sodium acetate,
52
 triethylamine,
53
 NaH, t-BuOLi or t-BuOk,
14,51
 and 
other bases have also been reported, such as silver oxide (Scheme 1.8)
54-57
 and 
palladium acetate (Scheme 1.8).
58
 The first NHC complexes reported by Wanzlick 
and Öfele have been prepared by this method.
21,53
 This method is remarkably 
favourable, considering the fact that air and moisture sensitive free carbenes can be 
by-passed. Most of the complexes of NHCs discussed in this work were prepared 
using this method. 
(c)   Transmetallation (NHC transfer reaction): 
        Lin and co-workers were the first to report this method in 1998.
54 
In this 
method, Ag2O was used as the basic metal source for the deprotonation of the 
azolium salts to give Ag-NHC complexes. This method has been successfully used 
with a variety of metals such as Rh, Ir, Pd, Pt, Ru, Cu and Au.
59,60
As a result of their 
lability, Ag(I)-NHC complexes are easily used as NHC transfer agents in the 
preparation of Pd (II) (Scheme 1.9), Au (I), Rh(I) and Ir(II) NHC complexes. This 
procedure has been extensively used due to the moderate reaction conditions, leading 
to the formation of more stable products. The absence of 
107,109
Ag-
13
C coupling in the 
13
C NMR and the labile nature of the Ag-NHC complexes was suggested to be one 
the reasons for the easy NHC transfer.
54
 The procedure is such that, a suitable 
azolium salt was treated with Ag2O, AgCO3 and AgOAc to obtain Ag(I)-NHC 
complexes. Thereafter, the obtained Ag(I)-NHC complexes were made to react with 
the other metal sources to give the proposed metal-NHC complexes.
61
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Scheme 1.8: Preparation of metal-NHC complexes by in-situ deprotonation    
                     method.
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The synthesis of Pd(II)–NHCs other than transmetallation method,  such as 
direct metalation of azolium salt with Pd(OAc)2 or with Pd(II)-precursor in the 
presence of external base were also investigated. The work by Gade and co-
workers,
62
 Tilset and co-workers,
63
 Cavell and co-workers
64
 and Shreev and co-
workers
65
 pointed out the inefficacy of direct metalation to prepare Pd(II)–NHCs. 
Consequently, transmetallation by Ag(I)–NHCs became a general interest. However, 
there are some short comings that were reported in using the transmetallation 
method. Hahn and co-workers,
66
 Bildstein and co-workers,
67
 Magil and co-workers
68
 
reported the low yield and non-success of transmetallation. Mata and co-workers also 
reported unsuccessful formation of a chelate complex with the intended metal-NHC 
complex.
69 
These failures were proposed to have been caused by the presence of a 
11 
 
strong Ccarbene-Ag bond. The Pd(II)-NHC complexes discussed in present work 
were obtained by this route. 
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Scheme 1.9: NHC transfer from Ag(I) centre to Pd(II) centre.
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1.6   Functionalized NHC complexes  
        Research on functionalised NHC complexes has developed rapidly over the last 
few years.
70-74 
The formation of NHC complexes by reacting NHC precursor with a 
number of donors in the ligand framework gives innovative coordination chemistry.
74
 
Functionalized NHCs with excellent donor groups of nitrogen and oxygen are 
exclusively diverse in number. In this work, the synthesis and structural 
characterisation of NHC complexes functionalized with oxygen and nitrogen donor 
groups are highlighted as important part of the present study.  
12 
 
1.6.1 Functionalized NHCs and metal complexes containing nitrogen donors 
The modelling of functionalized NHCs with nitrogen donor groups is given a 
considerable attention much more than phosphine donor groups. Especially, the 
inclusion of pyridine functionality into polydentate ligand framework of NHCs is of 
great significance.  This high interest in pyridine functionality could be partially due 
to the simple synthetic procedure associated with the ligand precursors and the 
interesting rigidity transmitted to the metal complexes from the chelate rings and 
addition to the exceptionally thermal stability.
72
 Pincer-type ligands based on 
pyridine–dicarbene have gained considerable attention as a result of the increased 
stability and a strengthened rigidity (Figure 1.4). Furthermore, NHC with a central 
imidazole ring and two flanking pyridine side-arms have been studied by several 
research groups.
68,75–78 
The ligand precursor (VII) forms Pd (II) complex (VIII) due 
to the small bite angle resulting in the bidentate coordination of the two ligands 
(Scheme 1.10).
75 
Complex (VIII) shows a fluxional behaviour in solution because of 
the hemilabile characteristic of the ligand with the coordinated and free pyridine 
arms.
75
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 Figure 1.4: Pyridine NHC ligands. 
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Scheme 1.10: Formation of Pyridine functionalized Pd(II)-NHC complex.
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Apart from pyridine functionality, other varieties of functionalized NHCs 
with nitrogen donor groups, like imine, amide, nitrile, oxazoline, pyrazole, and amine 
are also well-known.
79,80 
The first amide functionalised NHC (IX) was reported by 
Arnold et al. and was prepared in good yield by the alkylation of tert-butyl imidazole 
with t-BuNHCH2CH2Br.HBr.
81
 Fryzuk et al. was able to establish the first models of 
tridentate bis-amine NHC precursor (X). In 2009 Wylie et al. reported the synthesis 
of unsymmetrical nitrile functionalized NHC precursor (XI) from 2-
cyanophenylimidazole (Figure 1.5). The reactions of these novel imidazolium salt 
with Ag2O yielded novel Ag(I)-NHC complex (XII).
82 
Although an analogous 
nitrile-functionalized NHC complex of Pd(II) (XIII) was reported earlier by Dyson 
and co-workers.
83
 See Figure 1.6 below. 
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Figure 1.5: Examples of N-functionalized NHC precursors. 
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 Figure 1.6: Examples of N-functionalized Ag(I)-NHC and Pd(II)-NHC complexes. 
 
1.6.2 Functionalized NHCs and metal complexes containing oxygen donors 
Functionalized NHCs bearing oxygen donors, like ester,
84,85
 ether,
73,86,87
 
hydroxyalkyl
88, 89
 and ketone components
85,90
 have been reported. In most cases for 
the complexes, the oxygen functionalities of these NHC precursors are not 
coordinated
84,86,89,90
(Figure 1.7) but complexes with the chelated oxygen 
functionalities are also known.
90,91 
Früstner et al. showed that ester functionality can 
also be connected with the NHC moiety.
84 
Takacs et al. also reported the preparation 
of acylfunctionalized NHC precursor
88
 and was found as an effecient Pd-catalyzed 
Suzuki-Miyaura coupling reactions. According to cited literatures above, it is worthy 
of note to mention that most of the research on functionalized complexes have been 
directed towards catalysis. So far research involving functionalized NHC complexes 
for biological studies is quite rare. 
 
 
 
 
15 
 
NHN +
O
ONHN
O
Ph
mes O
O
Br Br
XIV XV
+
 
.  
NN
O
OO
O
N N
O
O O
O
Ag +AgBr2
NN
O
OO
O
N N
O
O O
O
Pd ClCl
 
 XVI                                                                       XVII 
Figure 1.7: Examples of O-functionalised Ag(I)-NHC and Pd(II)-NHC complexes. 
 
1.7   Antibiotics  
        Antibacterial agents, or antibiotics, are a class of a larger group of compounds 
called antimicrobial agents. Earlier, antibiotics were referred to as only naturally 
occurring molecules produced by a variety of microorganisms.
92
 However, the term 
has transformed to include man-made synthetic compounds.
93
 Antibiotics can be 
categorised into four distinct classes based upon their mechanism of action. Those 
four classes are (1) the agents that inhibit bacterial cell wall biosynthesis, (2) the 
agents that inhibit protein biosynthesis, (3) the agents that inhibit deoxyribonucleic 
acid (DNA) or ribonucleic acid (RNA) synthesis, and (4) the agents that inhibit folate 
synthesis.
93
 
Inhibitors of Bacterial Cell Wall Biosynthesis: 
 β-lactam antibiotics act on diverse targets within the biosynthetic cascade of 
cell wall formation. This family of compounds is comprised of four groups of 
16 
 
molecules: (1) the penicillins, (2) the cephalosporins, (3) the carbapenems, and (4) 
the monobactams. They all act via the same mechanism of action, and that is by 
binding and inhibiting the penicillin binding proteins (PBPs); more specifically they 
inhibit peptidoglycan transpeptidase causing lysis and cell death.
93
 
Inhibitors of Protein Biosynthesis: 
This class of compounds exert their antibacterial action by blocking one or 
more of the steps in protein biosynthesis that occur on either the 30S or 50S subunits 
of the bacterial ribosome. There are a number of families of molecules that make up 
this family including the macrolides, lincosamides, streptogramins, oxazolidinones, 
aminoglycosides, and tetracyclines.
93
 However, the major families that compose this 
family are the aminoglycosides, macrolides, and tetracylines. These antibiotics show 
potent activity against gram-negative bacteria, but lack potent activity against most 
gram-positive bacteria. However, they are used in combination with β-lactams to treat 
some enterococcal infections.
93
  
Inhibitors of DNA and RNA Synthesis:   
This class of antibiotics works on one of three targets: DNA gyrase, 
topoisomerase IV, or DNA-directed RNA polymerase. There are two families of 
antibiotics included within this class, and those are the quinolones and the 
rifamycins. The activity of the quinolones is derived from their inhibition of DNA 
gyrase and topoisomerase IV.
92
 While DNA gyrase and topoisomerase IV have 
similar mechanisms of action, the difference is the fact that DNA gyrase is more 
important for gram-negative organisms and topoisomerase IV is more important for 
gram-positive organisms.
94
 The quinolones work by binding to DNA gyrase or 
topoisomerase IV and preventing the supercoiling of DNA, thereby inhibiting 
synthesis of DNA.
93
 The quinolones were not widely used until the discovery of the 
17 
 
fluoroquinolones in the 1980s.
95
 There are presently four generations of quinolones 
that have been developed and are in clinical use. The rifamycin family of antibiotics 
works on DNA-directed RNA polymerase. These agents bind to the β-subunit of 
DNA-directed RNA polymerase and inhibit the initiation of chain formation in RNA 
synthesis.
93
 Rifamycin is a natural product with several natural analogs, but three 
semisynthetic analogs have since been synthesized. Those agents are rifampin, 
rifabutin, and rifapentine. These agents are front-line agents in the treatment of 
tuberculosis.
93
  
Inhibitors of Folate Synthesis: 
Folate is very important to the survival of all living organisms.
96
 It plays a 
considerable role in DNA synthesis by serving in the transfer of methyl, formyl, and 
other single-carbon fragments in the biosynthesis of purine nucleotides.
97
 Humans 
and bacteria obtain folate via different routes. Humans obtain folate through their 
diet, while bacteria synthesize folate through the folate biosynthetic pathway. This 
difference makes the folate biosynthetic pathway a very attractive drug target.
96
 
There are two enzymes in this pathway that are currently targeted by antibacterial 
agents: dihydropteroate synthesis (DHPS) and dihydrofolate reductase (DHFR). The 
family of agents that act on DHPS is the sulfonamides. DHFR is acted upon by a 
single agent, and that is trimethoprim.
92
 The sulfonamides work by inhibiting DHPS, 
which catalyses the conversion of p-aminobenzoic acid (PABA) to 
dihydroteroate.
98,99 
As a result of resistance issues, most of the originally developed 
sulfonamide drugs are no longer in use as a monotherapy. However, some are still in 
use for acne and urinary tract infections. The most commonly used drug in this class 
is sulfamethoxazole. This agent is often used in combination with trimethoprim, 
18 
 
which expands it antibacterial spectrum and reduces the potential for the 
development of drug resistance.
94 
 
 
1.8 Biological applications of Ag(I) and Pd(II)-NHC complexes 
1.8.1 Background 
Penicillin resistant staphylococcus aureus (S. aureus) strains were first 
reported in the 1940s. However, research on anti-microbial is considered to have 
started in 1928 with the accidental discovery of penicillin by Alexander Fleming.
100 
Anti-bacterial drug discovery reached its apex in the 1950’s and of the majority of 
these compound classes are still in use today.
101
 In 1959 methicillin was introduced 
but again S. aureus quickly developed resistance which was later referred to as 
Methicillin-resistant S. aureus (MRSA).
101,102
 Resistance by MRSAs were also 
reported in the earlier years of the 1980’s against such antibiotics like erythromycin, 
neomycin, gentamycin and ciprofloxacin in 1990’s.103 After the introduction of 
streptogramins and quinolones earlier in the 1960’s, no novel class of anti-bacterial 
agent was introduced into clinical practice until linezolid was launched in 2000. 
Considering the diversity of bacterial structures, drug discovery in this area requires 
agents with specific biomolecular targets or routes. Bacterial microorganisms have 
utilized anti-bacterial xenobiotics to develop a complex arsenal of defences to protect 
themselves from attack. Consequently, some researchers suggest the superior role of 
natural products, owing to evolutionary conditions, in producing an array of 
antibiotic producing microorganism, compared with synthetic libraries.
102
 However, 
these antibiotics function by targeting specific biomolecular pathways and as a result 
have a propensity for the development of resistance to prophylactic treatment.  
Later in 2002, it was reported that Vancomycin-resistant S. aureus (VRSA) 
was identified and isolated.
104,105 
Bacteria can develop resistance surprisingly fast, 
19 
 
arising through either an alteration of the target site or enzyme, inhibition of the 
antibiotics to gain access and destruction or deactivation of the antibiotics.
106
 
Therefore highly resistant pathogenic bacteria causing life threatening infectious 
diseases are appearing, especially, strains which are no more responding to treatment 
by any possible antibiotics. A number of studies have been carried out on the effect 
of bacterial infections, one example of such is the effect of S. aureus peritoneal 
infection on a mouse model, the studied revealed the presence of intraperitoneal 
abscesses in the vicinity of inoculation sites, a disease that occurs frequently in 
humans undergoing continuous ambulatory peritoneal dialysis for end-stage renal 
disease (Figure 1.8).
107
  
During the last two decades, numerous anti-bacterial agents have been 
developed and offered into the market, however their effectiveness has over the years 
deteriorated and failed to solve the problem of multidrug resistant bacteria.
108-110
 
Therefore, there is a need to develop novel anti-microbial compounds with an 
entirely different mechanism in order to curb the fatality of multidrug-resistant 
bacteria. In the light of this, organometallic derivatization was proposed as an 
attractive approach to subdue the resistance problem. This approach could possibly 
provide a metal mode of action which is specific and non-existence for the purely 
organic parent drug molecule.
111-114
 In certain conditions, it was suggested that the 
effectiveness of a metal-based-drug could be as a result of the original activity and 
the inherent toxicity of the inorganic metal.
114
 It has already been established that the 
potentiality of bacteria to cultivate resistance against silver-based anti-microbials is 
constrained, therefore affording such antibiotics to possess a long shelf life.
115,116 
The 
development of metal-containing anti-cancer and anti-malarial compounds has 
shown a lot of advancement.
117-122
 However, very little awareness has been shown 
20 
 
for the development of organometallic anti-bacterial drugs. Therefore, research on 
metal-based anti-bacterial compounds is very appropriate and desirable. 
To date a large number of studies have been carried out on Ag(I) complexes 
as potential anti-microbials, anti-cancer and their carbene transfer ability.
123-126
 Also 
Ag(I)-complexes have shown interesting DNA binding ability,
127-129
 however there is 
paucity of data on their ability to cleave the nucleic acids (DNA/RNA). On the other 
hand, the interaction of Ag(I)–NHC complexes with nucleic acids is a significant 
field of research to be explored to a greater extent due to the utility of these carbene 
complexes in the development of spectroscopic probes, diagnostic agents and site-
specific nucleic acid cleavers, among others.
130
 It is worthy of mentioning that apart 
from DNA there are some other biological targets including RNA, enzyme or 
protein. Therefore it is considered worthwhile to investigate the interaction of these 
synthesized compounds with DNA and/or RNA as an initial experiment to study the 
likely mode of action(s) of the reported compounds.  
 
 
Figure 1.8:  Staphylococcal lesions associated with the kidney.
107
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1.8.2 Biological applications of Ag(I)-NHC complexes 
Biological studies of Ag(I)–NHC complexes are established on the 
knowledge that elemental silver and its salts have long been recognized for their 
potential in the protection of the eyes of newborns from infection, as well as their 
anti-microbial properties, essentially against chronic ulcers, extensive burns, and 
wounds.
131,132 
This astounding activity of silver or Ag(I)–NHC complexes against 
bacteria, fungi, and yeast is due to slow delivery of silver cations across the cell 
membrane, which mostly interferes with the electron transport system of the cell and 
also interacts with the thiol groups of the vital enzymes of bacteria.
133
 Ag(I)-NHC 
complexes offers encouraging results to overcome the problems of drug resistance of 
some pathogenic bacteria, which has so far eluded the effectiveness of 
sulphonamides. Recently, Ag(I)–NHC/coordination complexes have been found to 
display potential anti-microbial activity, particularly for the potential treatment of 
cystic fibrosis and chronic lung infections,
134,135
 which makes them appropriate 
entities for drug development.
136
 The enhanced stability of the complexes is 
anticipated to be useful for anti-microbial activity, because silver is released 
gradually as compared to ionic silver complexes such as AgNO3 which is 
spontaneous in action but lose their effectiveness quickly resulting in 
reinfection.
137,138
 Youngs research group was the first to report Ag-NHC in 2004 for 
anti-microbial studies.
139
 One example of such series of compound (XXII) is shown 
in Figure 1.11 below. In this work Youngs recorded a highly promising results from 
this caffeine derived Ag-NHC which showed excellent anti-bacterial activity against 
drug resistant pathogenic bacteria.
140,141
 The search for better biologically active 
Ag(I)-NHC complexes led to the synthesis of modified caffeine silver acetate 
complex.
134
  Gosh and co-workers also synthesized Ag(I)-NHC complexes of 1-
22 
 
benzyl-3-tert-butylimidazolium chloride and tested on analytically important 
microorganism.
142
 The Ag(I)-NHC complexes derived from 4,5-dichloroimidazole 
have been synthesized, having water stability for up to three days and this was 
attributed to the presence of electron withdrawing substituents present on the 4- and 
5-positions of the imidazole ring.
141
 In recent years, varieties of functionalized NHC 
complexes with bidentate chelating NHCs, tripodal NHCs, pincer type NHCs have 
also been investigated,
71,143-147
 especially in catalysis while their anti-microbial 
properties are less explored. The effectiveness of the anti-microbial properties of 
Ag(I) complexes may be influenced by the type of ligands that bind to Ag(I) ion.
148
 It 
was found that the type of substituents and chain length of alkyl chain have a 
significant effect on their anti-microbial properties.
149,150
 Modification of NHCs can 
be easily achieved by introducing functional groups at the nitrogen atoms of the 
imidazole ring,
16,146,151
 thereby fine-tuning the characteristic features like 
lipophilicity, charge, solubility of the spacers (bridging groups) and substituents. 
This has stimulated the design of complexes in favour of reaching a compromise 
between biological activity and toxic effects.
151
 Examples of metal based antibiotics 
are shown in Figure 1.9 below. 
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 Figure 1.9: Sulfadiazine (XVIII) and Silver sulfadiazine complex      
                       (XIX). 
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A very fascinating characteristic of NHC chemistry is the simplicity with 
which a number of complexes with similar structures and different lipophilicity 
(Figure 1.10 & 1.11) can be synthesized by changing the substituents on the 
imidazolium salts.
14,16
 The lipophilicity of a substance cannot be overlooked as one 
of the influential parameters in its biological activity.
134,141,143
 The enhanced 
lipophilicity characters of some compounds have been found to have positive 
correlation with their anti-bacterial activity.
152,153
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Figure 1.10: The first Ag(I)-NHC complexes used as anti-microbial agents.
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Figure 1.11: Examples of Ag(I)-NHC complexes exhibiting significant anti-  
                    microbial activity. 
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Both functionalized and nonfunctionalized imidazole based NHCs, as well as 
their metal derivatives of wide structural diversity, have been studied as therapeutic 
agents for cancer treatment. Specifically, functionalized NHC ligands have attracted 
special interest from the point of view of tuning the coordination environment around 
the core metal, because of their flexible chelating nature. In principle, the 
lipophilicities and reactivities of Ag(I)–NHC complexes can be tuned systematically 
by changing the attached NHCs or substituents. Therefore in the present work, 
numerous varieties of Ag(I)–NHC complexes have been synthesized to determine the 
possible involvement of functional and non-functional substituents present  at the N 
atom(s) of the [benz]imidazolium core. 
 
1.8.3 Biological application of Pd(II)-NHC complexes 
A number of complexes based on Pd(II) have been synthesized and their 
different biological activities have been documented.
154,155,156 
The effect of various 
palladium complexes on the growth and metabolism of different groups of microbes 
has been investigated. In 2009 Garoufis et al. reviewed diverse scientific papers on 
anti-viral, anti-bacterial and antifungal activity of Pd-(II) complexes with various 
types of ligands (sulfur and nitrogen donor ligands, Schiff base ligands and drugs as 
ligands).
157
 Over the past few years, literature has shown different activities of Pd-
(II) complexes against several species of bacteria and fungi.
158-166 
Although the 
biological activity of Pd-based drugs bearing a variety of ancillary ligands has been 
under intense investigation, only two reports of Pd-(II)-NHC complexes with anti-
bacterial activity is found in recent literature (Figure 1.12).
167,168
 Ghosh was the first 
to explore the cytotoxic capacity of two Pd complexes, XXVI and XXVII against 
three human tumor cell lines.
168
 To date, numerous Pd(II)–NHC complexes have 
been reported for various activities. However, this field of chemistry has been 
